SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease

PHASE2UnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

November 30, 2017

Conditions
Peripheral Arterial Disease
Interventions
BIOLOGICAL

JVS-100

Biological/Vaccine: JVS-100 Intramuscular Injection

BIOLOGICAL

Placebo

Biological/Vaccine: Placebo Intramuscular Injection

Trial Locations (24)

33614

RECRUITING

St. Joseph's Hospital, Tampa

Unknown

NOT_YET_RECRUITING

Cardiovascular Associates of the Southeast, Birmingham

RECRUITING

UC Davis, Davis

RECRUITING

Cedars-Sinai Heart Institute, Los Angeles

NOT_YET_RECRUITING

MedStar Georgetown UH, Washington D.C.

RECRUITING

Morton Plant Hosptial - Baycare, Clearwater

RECRUITING

Mount Sinai Medical Center, Miami

RECRUITING

Northwestern, Chicago

RECRUITING

RUMC, Chicago

RECRUITING

Cardiovascular Institute of the South, Houma

RECRUITING

St. John Hospital and Medical Center, Detroit

RECRUITING

Mayo, Rochester

RECRUITING

Cardiology Associates Research, Tupelo

RECRUITING

St. Luke's Mid America Heart Institute, Kansas City

RECRUITING

Holy Name Medical Center, Teaneck

RECRUITING

UNC, Chapel Hill

RECRUITING

NC Heart and Vascular Research, Raleigh

RECRUITING

Summa Health, Akron

RECRUITING

Cleveland Clinic, Cleveland

RECRUITING

Metro Health, Cleveland

RECRUITING

University Hospitals, Cleveland

RECRUITING

Lifespan Health System, Providence

RECRUITING

VCU, Richmond

RECRUITING

Medical College of Wisconsin, Milwauke

Sponsors
All Listed Sponsors
lead

Juventas Therapeutics, Inc.

INDUSTRY